Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		25 Months Ended	166 Months Ended
	Sep. 30, 2011 Successor	Sep. 30, 2010 Successor	Sep. 30, 2011 Successor	Sep. 30, 2010 Successor	Sep. 30, 2011 Successor	Aug. 31, 2009 Predecessor
Revenue
Product sales	$ 159,400	$ 243,677	$ 621,310	$ 716,809	$ 1,887,620	$ 4,818,994
License fees			0	0	0	260,000
Total revenue	159,400	243,677	621,310	716,809	1,887,620	5,078,994
Cost of sales	96,631	118,916	320,242	395,351	1,004,938	2,279,335
Gross profit	62,769	124,761	301,068	321,458	882,682	2,799,659
Selling, general and administrative expenses	3,920,986	1,583,418	9,540,713	5,424,661	18,764,650	84,805,520
Research and development expenses	1,892,859	1,387,466	5,111,053	4,053,817	12,420,568	56,269,869
Operating loss	(5,751,076)	(2,846,123)	(14,350,698)	(9,157,020)	(30,302,536)	(138,275,730)
Other income/(expense)
Interest income			0	0	1	6,989,539
Reorganization items, net			0	3,303	(69,174)	73,538,984
Other income			0	0	244,479	316,338
Warrant income	10,621,558	1,265,571	814,676	1,560,757	30,360	0
Derivative revaluation expense	2,316,428	0	(5,865,710)	0	(5,865,710)	0
Interest expense	(264,998)	(211,919)	(822,067)	(612,917)	(2,114,440)	(18,790,218)
Loss from continuing operations before income taxes			(20,223,799)	(8,205,877)	(38,077,020)	(76,221,087)
Income tax benefit			0	0	0	190,754
Loss from continuing operations	6,921,912	(1,792,471)	(20,223,799)	(8,205,877)	(38,077,020)	(76,030,333)
Loss from discontinued operations	(10,864)	(8,575)	(29,063)	(38,121)	(89,981)	(41,091,311)
Net income/(loss)	6,911,048	(1,801,046)	(20,252,862)	(8,243,998)	(38,167,001)	(117,121,644)
Deemed dividend associated with beneficial conversion			0	0	0	(11,423,824)
Preferred stock dividends			0	0	0	(1,589,861)
Net (income)/loss attributable to noncontrolling interest	5,809	(20,859)	(40,743)	(37,247)	(108,134)	1,799,523
Net income/(loss) attributable to Fibrocell Science, Inc. common shareholders	$ 6,916,857	$ (1,821,905)	$ (20,293,605)	$ (8,281,245)	$ (38,275,135)	$ (128,335,806)
Per share information:
Net income/(loss) from continuing operations - Basic	$ 0.10	$ (0.09)
Net income/(loss) from continuing operations - Diluted	$ 0.08	$ (0.09)
Loss from continuing operations-basic and diluted			$ (0.40)	$ (0.45)	$ (1.37)	$ (4.30)
Net income/(loss) attributable to common shareholders per common share-Basic	$ 0.10	$ (0.09)
Net income/(loss) attributable to common shareholders per common share-Diluted	$ 0.08	$ (0.09)
Loss from discontinued operations-basic and diluted			$ 0.00	$ 0.00	$ 0.00	$ (2.32)
Income (loss) attributable to noncontrolling interest					$ 0.00	$ 0.10
Deemed dividend associated with beneficial conversion of preferred stock			$ 0.00	$ 0.00	$ 0.00	$ (0.65)
Preferred stock dividends			$ 0.00	$ 0.00	$ 0.00	$ (0.09)
Net loss attributable to common shareholders per common share - basic and diluted			$ (0.40)	$ (0.45)	$ (1.37)	$ (7.26)
Weighted average number of basic common shares outstanding	69,863,597	19,557,842
Weighted average number of diluted common shares outstanding	89,671,791	19,557,842
Weighted average number of basic and diluted common shares outstanding			51,219,473	18,291,301	27,767,571	17,678,219